http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2247946-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9cce74ae91129e276612f5855529149a
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02C2202-10
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02C7-104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02C7-046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02C7-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G02C7-04
filingDate 2005-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99509043af45f28198d81a490f25890a
publicationDate 2006-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber ES-2247946-A1
titleOfInvention THERAPEUTIC CONTACT LENS FOR PSEUDO-AFAQUIC EYES AND / OR IN NEURODEGENERATION PROCESS.
abstract The object of the invention is a contact lens for pseudo-aphakic eyes and / or with macular and retinal degeneration characterized by being the result of the application of a filter with yellow pigmentation on a common contact lens, in order to protect them from short wavelengths of the visible spectrum (less than 500nm). This invention avoids the difficulties and risks of existing techniques to provide this protection to cataract operated eyes and to improve that of those in neurodegenerative processes, achieving it with the simple application of a contact lens. The invention consists of the combination of a common contact lens and a yellow pigmentation filter that absorbs short wavelengths of 350 / 500nm, both suitable for use in the human eye.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11054557-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11662507-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014096475-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014096477-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3982426-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-202013102610-U1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11035990-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3125005-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2312284-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150095939-A
priorityDate 2005-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H01204668-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23611
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16130922
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422600808
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448707737
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87424231
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419531591
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136229972
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432751576

Total number of triples: 35.